Hsp90 inhibitor-lenalidomide conjugate (Madrigal)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameHsp90 inhibitor-lenalidomide conjugate (Madrigal)
Drug Alias NameHsp90 inhibitor-lenalidomide conjugate (Synta)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP90 inhibitorsCereblon modulators
TargetsHeat shock protein HSP90Cereblon
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMadrigal Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMadrigal Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A